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Neoplasms of the mammary gland represent the most frequent tumor type in the female 
dog, and according to the histologic criteria, approximately 50% of them are malignant. 
In the most aggressive cases of mammary cancer, surgery is not enough to warrant a 
favorable outcome, and adjuvant therapies are needed to improve the patient’s overall 
survival. The aim of the present study was to evaluate the effects of two peptides on 
proliferation of a canine mammary cancer cell line derived from a simple carcinoma. The 
cell line CMT-U27 was grown in 96-well plates, at two cell densities (4 × 103 and 8 × 103 
cells/well). Cultures were treated with oxytocin (OT) or desmopressin at five concentra-
tions (10, 50, 100, 500, and 1000 nM). After 72 h of incubation, cell proliferation was 
determined by the MTT assay. Results showed that with 4 × 103 cells/well, OT at 50, 
500, and 1000 nM was growth inhibitory for the cells, being statistically significant at 
1000 nM. On the contrary, no antiproliferative effect was observed with 10 or 100 nM. 
At 8 × 103 cells/well, OT showed a significant antiproliferative effect only with the highest 
concentration (1000 nM). Desmopressin at 4 × 103 cells/well decreased cell viability at 
concentrations of 50, 100, 500, and 1000 nM (statistically significant with the highest 
concentration), while no effect was observed with 10 nM. With 8 × 103 cells/well, this 
peptide reduced cell growth at 100, 500, and 1000 nM. In conclusion, we suggest that 
these peptides may be potential and promising compounds for the treatment of dogs 
with simple carcinomas of the mammary gland. In vivo studies are required to confirm 
this hypothesis.
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inTrODUcTiOn
Mammary gland tumors are the most common neoplasms in intact female dogs, and approximately 
50% of them are malignant. The treatment of choice for mammary gland tumors is surgical exci-
sion. However, in malignant cases, surgery alone is not enough to warrant a favorable outcome, and 
adjuvant therapies are needed to reduce the risk of recurrence or metastasis (1, 2). In women with 
aggressive breast cancer, postoperative chemotherapy is routinely administered to improve disease 
free and overall survival rates (3). In bitches, although several chemotherapy protocols have been 
2
Benavente et al. Antiproliferative Effects of Two Peptides
Frontiers in Veterinary Science | www.frontiersin.org December 2016 | Volume 3 | Article 119
tested (4–6), most of them did not show real benefits in survival 
time or have high toxicity and side effects. A recent study has 
described a longer overall survival in dogs treated with surgery 
and carboplatin, than those treated with surgery alone, indicating 
that this chemotherapeutic agent may be beneficial for the treat-
ment of malignant mammary tumors (7).
Hormonal therapy is a well-established adjuvant treatment 
for women with estrogen receptor—positive tumors (hormone-
dependent breast cancer), and tamoxifen is one of the antiestro-
gens most commonly used (8). However, the use of tamoxifen is 
restricted in female dogs due to its side effects, which includes 
vulvar swelling, vulvar discharge, and pyometra, among others 
(9). Therefore, it is essential to concentrate on the development 
of safe and effective adjuvant treatments for dogs with mammary 
cancer, in order to reduce the risk of recurrence or metastasis.
A number of in vitro studies performed on murine and human 
cancer cells have suggested that some peptide hormones can 
modulate tumor growth (10–12), by interacting with its mem-
brane receptors. However, little is known about the effects of these 
peptides on canine mammary cancer.
Oxytocin (OT) is a peptide hormone mainly synthetized in the 
hypothalamus, which plays a key role in uterine contraction and 
milk ejection, among other functions (13). However, in recent 
years, a new role for OT has been described in relation to the 
carcinogenic process. Several studies have demonstrated that 
OT could stimulate, inhibit, or have no effect on neoplastic cell 
growth, and these diverse effects seem to be mediated by different 
signaling pathways. In neoplastic cells derived from trophoblast 
and endothelium, OT was found to promote cell proliferation (14, 
15). On the contrary, in human neoplastic cells of mammary (16), 
nervous (17), and bone origin (18), OT inhibited the cell growth. 
Moreover, in  vivo experiments showed that the subcutaneous 
administration of OT in Balb-c mice bearing breast carcinomas 
can reduce tumor growth (19). In addition, the presence of OT 
receptors has been described, both in human primary breast 
carcinomas and cell lines (20). According to these findings, 
OT appears to be involved in mammary tumor growth. To our 
knowledge, there is only one report about the effects of OT on the 
proliferation of canine mammary cancer cells.
Desmopressin [1-d-amino-8-d-arginine vasopressin 
(DDAVP)] is a synthetic analog of the antidiuretic hormone 
vasopressin, which has been used in humans and dogs for the 
management of diabetes insipidus (21). In addition, DDAVP 
has various effects in the hemostatic system, causing the release 
of coagulation factors VIII and von Willebrand (22). Due to its 
hemostatic properties, DDAVP has also been used in patients 
with different bleeding disorders (23). Interestingly, in a mouse 
model of breast cancer, DDAVP inhibited lung colonization by 
neoplastic cells (24). Since then, a number of studies have shown 
that this peptide seems to have antimetastatic and antiprolifera-
tive effects, both in mouse models of breast cancer and in different 
breast cancer cell lines (25, 26). Furthermore, a veterinary clinical 
trial has demonstrated that the perioperative administration of 
DDAVP increases the disease free and overall survival time in 
surgically treated bitches with mammary cancer of various his-
tological types (27). Considering all these information, DDAVP 
could represent an excellent compound for surgical adjuvant 
therapy for the management of bitches with malignant mammary 
tumors.
The aim of the present study was to investigate the effects of 




The canine mammary tumor cell line CMT-U27 was used in this 
study, which was generously supplied by Prof. Eva Hellmén. This 
cell line was established from a simple ductal carcinoma at the 
Swedish University of Agricultural Sciences (SLU) in Sweden 
(28). In previous studies, CMT-U27 cells have shown a high 
growth rate and antiapoptotic potential (29).
cell culture conditions
CMT-U27 cells were routinely cultivated in RPMI-1640 medium 
(Sigma-Aldrich) supplemented with 10% fetal bovine serum 
(FBS) (Natocor, Argentina), 100  UI/ml penicillin and 100  µg/
ml streptomycin (Sigma-Aldrich). Cells were cultured in 25 cm2 
cell culture plastic flasks (Corning Inc., USA) in a humidified 
incubator (Panasonic, Lobov Científica, Argentina) with 5% CO2 
at 37°C.
Peptides
Oxytocin was supplied by Chemo Romikin S.A. (Buenos Aires, 
Argentina) and desmopressin (Elea Laboratories, Argentina) 
was kindly provided by Dr. Daniel Alonso, from Laboratory 
of Molecular Oncology, Quilmes National University (Buenos 
Aires, Argentina). Both peptides were supplied in the lyophilized 
form, and at the beginning of the assays they were dissolved in 
sterile phosphate buffer saline (PBS) pH 7.4 at a final concentra-
tion of 100 µM, and then aliquots were stored at −20°C for no 
more than 1 month.
cell Proliferation assay
Cell viability was measured using the MTT (3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide) colorimetric dye 
reduction method, as previously reported (26, 30). The medium 
was removed from the flasks, cells were washed with 3 ml of sterile 
PBS and then detached using EDTA for 5 min. Cell number was 
determined using a hemocytometer. Then, CMT-U27 cells were 
seeded into 96-well plates at two densities (4 × 103 and 8 × 103 
cells/well) in 200 µl of RPMI-1640 supplemented with 10% (v/v) 
FBS and incubated in a humidified atmosphere at 37°C under 5% 
CO2 and 95% air to allow cell adhesion. After overnight culture, 
the medium was removed and replaced with 200 µl of medium 
containing OT or DDAVP at five concentrations: 10, 50, 100, 500, 
and 1000 nM, or medium without drugs (controls). The cells were 
incubated for 72  h. Afterward, MTT (Sigma-Aldrich) (20  µl) 
was added to each well and incubated for 2 h at 37°C to allow 
MTT to form formazan crystals by reacting with metabolically 
active cells. To complete solubilization of the formazan crystals, 
100 µl of isopropanol were immediately added to each well. Cell 
viability was quantified by measuring the absorbance at 595 nm in 
FigUre 2 | effect of oxytocin (OT) on in vitro growth of canine 
mammary cancer cells. CMT-U27 cells were grown in 96-well plates 
(8 × 103 cells/well) with appropriate concentrations of OT. MTT assay was 
performed after 72 h. (*) Indicates values statistically different from the control 
group (p < 0.05). Values represent means ± SE from 12 replicate 
measurements from four independent experiments.
FigUre 1 | effect of oxytocin (OT) on in vitro growth of canine 
mammary cancer cells. CMT-U27 cells were grown in 96-well plates 
(4 × 103 cells/well) with appropriate concentrations of OT. MTT assay was 
performed after 72 h. (**) Indicates values statistically different from the 
control group (p < 0.01). Values represent means ± ΣE from 12 replicate 
measurements from four independent experiments.
FigUre 3 | effect of desmopressin [1-d-amino-8-d-arginine 
vasopressin (DDaVP)] on in vitro growth of canine mammary cancer 
cells. CMT-U27 cells were grown in 96-well plates (4 × 103 cells/well) with 
appropriate concentrations of DDAVP. MTT assay was performed after 72 h. 
(*) Indicates values statistically different from the control group (p < 0.05). 
Values represent means ± SE from 12 replicate measurements from four 
independent experiments.
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a multi-well plate reader (Beckman Coulter, DTX 880 Multimode 
Detector). All the samples were examined in triplicate, and each 
experiment was conducted four times. The optical density of 
formazan formed in untreated control cells was considered as 
100% viability. The optical densities from the treated cells were 
converted to a percentage of living cells against the control.
statistical analyses
Data from the four independent experiments was analyzed by 
one-way analysis of variance contrasted with Dunnett Multiple 
Comparisons Test at a significance level of p < 0.05. The values 
were evaluated for approximate normality of distribution by the 
Kolmogorov–Smirnov test.
resUlTs
effect of OT on canine Mammary cancer 
cells
At 4 × 103 cells/well, a decrease in cell growth was observed with 
OT at concentrations of 50, 500, and 1000  nM. However, the 
inhibitory effect was statistically significant only with the highest 
concentration of the hormone (p < 0.01), which resulted in a 25% 
of inhibition of cell viability. OT did not affect the proliferation of 
CMT-U27 cells at 10 and 100 nM (Figure 1).
Regarding the experiments with 8  ×  103 cells/well, no sig-
nificant antiproliferative effect was obtained with OT at 10, 50, 
100, and 500 nM. On the contrary, the highest concentration of 
OT (1000 nM) caused a significant inhibition of CMT-U27 cell 
growth (almost 25%) (p < 0.05) (Figure 2).
effect of Desmopressin on canine 
Mammary cancer cells
At 4  ×  103 cells/well, DDAVP at concentration of 1000  nM 
resulted in a significant antiproliferative effect (22%) (p < 0.05). 
The growth of mammary cancer cells was not affected by the addi-
tion of DDAVP at 10, 50, 100, and 500 nM (Figure 3).
At 8 × 103 cells/well, nearly 15% of cell growth inhibition was 
obtained with DDAVP at 100, 500, and 1000 nM. However, this 
difference was not statistically significant (p > 0.05). DDAVP at 
10 and 50 nM did not show any significant effect on cell growth 
(Figure 4).
DiscUssiOn
This study provides information about the effects of two 
peptides on in  vitro growth of a canine mammary simple 
carcinoma cell line. The present results show that treatment of 
FigUre 4 | effect of desmopressin [1-d-amino-8-d-arginine 
vasopressin (DDaVP)] on in vitro growth of canine mammary cancer 
cells. CMT-U27 cells were grown in 96-well plates (8 × 103 cells/well) with 
appropriate concentrations of DDAVP. MTT assay was performed after 72 h. 
Values represent means ± SE from 12 replicate measurements from four 
independent experiments.
4
Benavente et al. Antiproliferative Effects of Two Peptides
Frontiers in Veterinary Science | www.frontiersin.org December 2016 | Volume 3 | Article 119
CMT-U27 cells with OT and DDAVP inhibited the proliferation 
of tumor cells.
As stated before, this canine cell line was isolated from a 
simple carcinoma, a histological subtype frequently diagnosed 
in female dogs, and associated with a short disease-free period 
after surgery (31). In previous studies, CMT-U27 cells showed 
to be sensitive to antiprogestins (32) and also to cyclooxygenase 
inhibitors and doxorubicin (33). For this reason, this cell line 
seems to be a useful in  vitro model to evaluate the effects of 
potential anticancer drugs.
To our knowledge, only one study reports on the effects of OT 
on this canine mammary cancer cell line, where a decrease in cell 
proliferation was observed at 1000 nM concentration, although 
this result was not consistent in all the assays performed (34). The 
author attributes these variations to different aspects of the cell 
line, including the stage of the cell cycle in which the cells were at 
the beginning of each assay, the moment in which the cells were 
last reseeded before the assay, or when the cell culture medium 
was changed in relation to the assay. Besides, this last study 
reported inhibitory effect with OT 100 nM. In the present study, 
a growth inhibitory effect with OT at 1000 nM was detected in 
all the assays, while no significant effect was observed at 100 nM. 
Both studies on canines are in agreement with experiments on 
human breast cancer cell lines, who reported the inhibitory effect 
of OT, even with minimum doses of 1 nM of OT (35). A more 
recent study demonstrated that both normal myoepithelial cells 
and breast carcinomas cell lines can synthesize OT and that 
estrogens can modulate this synthesis (36). Additional studies on 
CMT-U27 cells could include the evaluation of OT synthesis by 
the canine cancer cells and the effects of estrogens or progesterone 
on OT action.
This is the first report where the effects of desmopressin are 
evaluated on cultures of canine mammary cancer cells. When the 
cells were treated with increasing concentrations of DDAVP, a cell 
growth inhibition was observed. Previously, a study demonstrated 
a beneficial effect of perioperative administration of DDAVP 
(administered at doses of 1 µg/kg, 30 min before and 24 h after 
surgery) on survival in bitches with mammary cancer, without 
causing side effects (27). The results obtained in the present 
study seem to support the hypothesis that DDAVP can inhibit 
the growth of residual malignant cells, thus limiting tumor pro-
gression. More recently, a phase II dose-escalation trial in women 
with breast cancer was performed, demonstrating that DDAVP, 
administered 30–60 min before and 24 h after surgical resection, 
reduced intraoperative bleeding and the number of circulating 
tumor cells. Moreover, it appeared to be safe and well tolerated at 
the highest dose level evaluated (2 µg/kg) (37).
The in  vitro results of the present study are in agreement 
with those of other studies that have shown that the addition of 
DDAVP to mouse and human mammary cancer cells inhibits 
cell proliferation (38, 39). The antiproliferative action of DDAVP 
appears to be mediated trough the V2 vasopressin receptor, which 
involves the increase of intracellular cAMP concentrations (22). 
The presence of V2 vasopressin receptors has been demonstrated 
in the MCF-7 human breast cancer cell line (40). More recently, 
the novel [V4Q5] DDAVP analog has been synthesized and 
assayed in cultures of MCF-7, causing a significantly greater 
inhibition of cell proliferation than DDAVP, at concentrations 
of 500  nM or higher (26). Additional studies are necessary to 
investigate the presence of the V2 vasopressin receptor on canine 
mammary cancer cell lines and spontaneous mammary tumors 
and to evaluate the effects of the analog [V4Q5] dDAVP on in vitro 
growth of canine mammary cancer cells.
Besides, our experiments showed that at the lower cell density 
(4 × 103 cells/well), both OT and DDAVP 50 nM exhibited an 
antiproliferative effect similar to that obtained with 1000  nM 
(approximately 20%). Likewise, a biphasic pattern, observed at low 
cell density, has been reported recently on human prostate cancer 
cell lines treated with desmopressin, where low doses (1 nM) as 
well as a higher dose (1 µM) have an antiproliferative effect (41). 
This “biphasic effect” of peptides was shown some decades ago 
with OT on human uterus and oviduct (42). Afterward, this effect 
was described for other molecules in detail in 1977 (43). This 
biphasic dose response seems to occur when a single agonist has 
differential affinities for two opposite receptor subtypes, leading 
to different signaling pathways. Due to the fact that only one OT 
receptor is known, some authors have suggested that in some 
tissues and under particular circumstances, OT action could be 
mediated by vasopressin receptors, for which OT maintains a 
certain affinity (44).
To conclude, the present study shows that OT and desmopres-
sin inhibit the proliferation of the canine mammary cancer cell 
line CMT-U27, by almost 20% with the highest concentration 
(1000 nM). Further studies on this and other canine mammary 
cell lines are needed to evaluate its potential as antitumor agents, 
alone or combined with conventional cytotoxic drugs, in the 
treatment of dogs with advanced mammary carcinomas.
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